Pregabalin

在当下的中国医药产业语境中，传统制药企业的转型故事往往比单纯的Biotech创新更具复杂的张力。它们既要应对集采常态化对普药基本盘的冲击，又要为高风险的创新药研发寻找持续的“造血”机制。 在华润双鹤最新的业绩报表中，一个微妙且关键的结构性变化正在发生。这份变化不仅关乎一家老牌央企的战略抉择，更为行业提供了一个观察“后集采时代”存量企业如何实现高质量发展的切片。而撬动这一切的关键支点，指向了一款上市不足三年的专科药物——吉时达（溴夫定片）。 专科业务“上位” 翻阅华润双鹤2026年半年报，不难发现其业务结构的深层次调整已然显现。报告期内，公司专科业务收入达到17.4亿元，占比提升至31%，一举超越慢病业务，成为公司第一大主要业务板块。 这一“上位”并非偶然。在输液等传统优势领域面临存量竞争天花板的背景下，华润双鹤近年来坚定地执行了向“专科化”切换的战略。而支撑这一战略落地的核心驱动力，正来自于以吉时达为代表的高壁垒专科品种的爆发式增长。 数据显示，作为治疗带状疱疹的新一代抗病毒药物，吉时达在2025年销售收入已突破亿元大关，同比增长超350%；进入2026年，其增长势头依然强劲，一季度同比增速达62%，上半年收入同比增长超32%。 在当前医药行业整体增速放缓、大量品种陷入价格红海的环境下，一款专科药物能够保持如此高斜率的增长曲线，其战略意义远超财务数字本身，也标志着跑通了从“普药思维”向“专科思维”切换的商业逻辑。 “现金牛”助力创新 深入分析华润双鹤的转型路径，可以清晰地看到一种务实的“双轨制”策略：一方面，通过深耕高技术壁垒的专科药，打造能够产生稳定、丰厚现金流的“现金牛”产品；另一方面，利用这些确定性的商业回报，反哺高投入、长周期的创新药研发。 吉时达正是前者的典型代表。带状疱疹治疗药物溴夫定并非全新分子，但其原料药合成工艺复杂、制剂稳定性要求极高，在吉时达上市前，国内市场长期被进口产品独占。华润双鹤早在十多年前便以前瞻性的眼光锁定了这一品种，投入大量资源攻克了从原料到制剂的全链条技术难关，建立了严苛的质量控制体系。 这种对高壁垒品种的长期坚守，最终转化为市场上的独家竞争优势。吉时达凭借“每日一片、强效起始、无肾毒性”的差异化临床价值，迅速在医生和患者群体中建立起信任，在一个竞争相对温和的赛道里实现了价值最大化。 有了吉时达这样的强劲“造血”机器，华润双鹤在创新投入上显得底气更足。公司管理层在业绩说明会上透露，报告期内累计研发投入3.5亿元，投入强度达6.2%，其中战略性新兴产业研发投入占比已提升至31%。这种有意识的资源倾斜，正是得益于成熟专科品种提供的财务安全垫。 构建专科护城河 围绕吉时达在皮肤科和疼痛科建立的渠道优势与品牌影响力，华润双鹤成功打造了带状疱疹全病程管理的专科生态。 带状疱疹的临床痛点不仅在于急性期的皮损和抗病毒，更在于长期困扰患者的后遗神经痛（PHN）。2026年8月，华润双鹤公告显示，其研发的用于治疗神经病理性疼痛的一线药物——普瑞巴林缓释片已完成Ⅲ期临床试验。 这意味着，华润双鹤将手握“吉时达（急性期抗病毒）+普瑞巴林缓释片（慢性期镇痛管理）”的黄金组合，为临床提供覆盖带状疱疹全生命周期的解决方案。从吉时达的单点突破，到专科业务板块的整体崛起，华润双鹤的实践表明，对于具备产业基础的传统药企而言，创新转型不必是一场推倒重来的激进革命。通过精准卡位高壁垒专科赛道，以高质量产品赢得市场溢价，进而从容布局未来，是一条更为稳健且可持续的进化路径。

ROSEMONT, Ill., Oct. 20, 2026 /PRNewswire/ -- Over 3 million people have been diagnosed with hidradenitis suppurativa (HS) in the United States and today, the American Academy of Dermatology (AAD) and the Hidradenitis Suppurativa Foundation (HSF) have published the first-ever joint guidelines for the management and care of HS. HS is a skin condition that causes painful lumps deep in the skin, typically in areas of the body where skin rubs together like armpits, inner thighs, and the groin. Early diagnosis of HS is critical as it is often confused with acne or infection, causing people to go years without an accurate diagnosis. A board-certified dermatologist can both identify HS and screen for the medical and psychiatric conditions that often accompany it, giving patients access to comprehensive, individualized care sooner. "While hidradenitis suppurativa is a chronic condition, its painful symptoms are highly treatable," said AAD President and board-certified dermatologist Murad Alam, MD, MSCI, MBA, FAAD. "For millions of people with HS, dermatologists provide more than just a diagnosis. They provide expert, comprehensive care that allows patients to have a better quality of life." Compiled by a work group of 13 experts, including 12 board-certified dermatologists, the newly released guidelines, published in the Journal of the American Academy of Dermatology (JAAD), include 37 evidence-based recommendations designed to treat chronic HS disease and acute HS flares. "These guidelines establish an evidence-based standard of care for HS, giving patients, dermatologists, and payers a shared roadmap for what high-quality HS care looks like," said board-certified dermatologist Haley B. Naik, MD, FAAD, co-chair of the Hidradenitis Suppurativa Guideline Work Group and president of HSF. "Every person living with HS deserves care that meets this standard." The largest barrier to impactful HS care is step therapy, an insurance requirement for patients to try insurer-designated treatments before coverage is approved for the dermatologist-prescribed preferred medication. Evidence does not support the use of step therapy in HS care as it delays access to appropriate treatment. Strong recommendations of care Strong recommendations imply that treatment benefits clearly outweigh risks and burdens. These recommendations apply to most patients in most circumstances. Biologics (adalimumab, bimekizumab, infliximab, and secukinumab), injectable treatments that target the immune system, are strongly recommended for individuals with moderate-to-severe HS. These treatments are shown to reduce the number of abscesses and nodules by at least half, without any new abscess or tunnel development. Abscesses are painful lumps that grow, join together, and fill with fluid. Tunnels are hollow channels that form under the skin. Conditional recommendations of care Conditional recommendations imply that treatment benefits are closely balanced with risks and burdens. These recommendations apply to most patients, but the best course depends on what matters most to each individual, including their tolerance for side effects, treatment goals, and day-to-day circumstances. Topical therapies (clindamycin, resorcinol, and ruxolitinib) are applied to the skin to reduce abscesses and the severity of symptoms. Systemic antibiotics (doxycycline, tetracycline, clindamycin in combination with rifampin, and ertapenem) work throughout the body to decrease severity of symptoms and improve quality of life. Hormone therapy (spironolactone) is taken by mouth to decrease severity. Systemic therapies (upadacitinib and short-term systemic steroids) are taken by mouth and work throughout the body for individuals with moderate-to-severe HS to reduce disease activity and pain. Continuing injectable biologics (adalimumab) is recommended for individuals with moderate-to-severe HS undergoing surgery. In-office procedures can be especially helpful if abscesses and tunnels have formed in the skin, including: Deroofing, a minor treatment to open and flatten the tunnels under the skin. This treats recurrent or persistently bothersome HS lesions, or bumps, spots, or growths. Incision and drainage to treat painful abscesses. Surgical removal of an area of affected skin for abscesses or tunnels that persist or continue to come back. Laser hair removal for fewer flares. Botulinum toxin to reduce flares. Intralesional triamcinolone (a steroid injection) to treat painful, flaring bumps. Conditional recommendations were made against the use of oral retinoids (acitretin and isotretinoin), certain biologics (etanercept, guselkumab, risankizumab, and vilobelimab), systemic therapies (avacopan, and methotrexate and azathioprine as primary treatments), and radiotherapy for pediatric and adolescent HS patients. In addition, there is insufficient evidence to support oral contraceptive pills or finasteride (hair loss medication) for HS management. Supportive management While HS therapies may reduce pain, they don't always achieve adequate pain relief. Supportive pain management is a conditional recommendation that helps manage sudden pain, consistent pain, and pain that does not improve after treatment and pain relief therapies. Treatments to manage sudden pain include warm or cool compresses, topical lidocaine (a local anesthetic), acetaminophen (a pain reliever), nonsteroidal anti-inflammatory drugs like aspirin and ibuprofen, steroid injections, incision and drainage, and short-term steroids that work throughout the body. Opioids can be used if the pain doesn't decrease through other treatments. Long-lasting pain can be managed with serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, psychotherapy, proper wound care, and nerve pain medications such as gabapentin and pregabalin. There is insufficient evidence to support weight reduction and GLP-1 usage for HS treatment. There is also insufficient evidence that specific diet plans — intermittent fasting, the Mediterranean diet, the yeast exclusion diet, and the dairy-free diet — help manage HS. However, a heart-healthy diet of fruits and vegetables, whole grains, healthy fats, and lean proteins remains important for reducing heart and diabetes risk for individuals with HS. Complementary medicine Lifestyle changes and supplements can also help manage the pain and discomfort from HS. A conditional recommendation was made for quitting tobacco, which can improve an individual's response to treatments aimed at addressing the disease itself. Conditional recommendations were made for complementary and alternative medicine, including vitamin D supplements for individuals with deficiencies, and zinc supplements. These supplements, taken under a doctor's supervision, may reduce lumps and tunnels and relieve pain. "Untreated HS can have a serious impact on your health and well-being. It can cause scarring, wounds that limit your mobility, and intense pain. It also often happens in combination with other medical and psychiatric conditions, with this increasing its overall toll on patients," said Dr. Alam. "Whether you've been diagnosed with HS or suspect you may have it, please take the time to see a board-certified dermatologist to have it expertly assessed, consider your options, and find the best plan for you." To find a board-certified dermatologist in your area, visit aad.org/findaderm. Resources Hidradenitis Suppurativa: Overview (AAD) How to Treat HS (HSF) Find an HS Provider (HSF) About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,500 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest, and YouTube, and @AADskin1 on Instagram. About the Hidradenitis Suppurativa Foundation Since its founding in 2005, the Hidradenitis Suppurativa Foundation has fostered and encouraged worldwide research by developing and supporting an interdisciplinary family of scientists and physicians devoted to studying Hidradenitis Suppurativa, in order to deliver more effective forms of treatment and preventative measures to those with this common, debilitating, and eminently chronic disease. HSF is a 501(c)(3) dedicated to improving the lives of people affected by Hidradenitis Suppurativa (HS) through research, education, and advocacy. Explore their resources for patients, clinicians, and investigators at hs-foundation.org, and follow @hsforg on Instagram and YouTube, and @HidradenitisSuppurativaFoundation on Facebook and LinkedIn. SOURCE American Academy of Dermatology 21% more press release views with Request a Demo